My area of research interest is in gastrointestinal motility and emesis. In the gastrointestinal motility research, I have established many in-vitro techniques. I have developed probably the best model to study highly complex and extremely useful peristaltic reflex in many species including guinea -pigs and mice and in various gastrointestinal regions including the ileum and colon.In the emesis side, our focus had been on developing new antiemetic therapy. We have investigated neurokinin and various other agents in collaboration with different pharmaceutical industries. Another area of expertise in the emesis research had been in the dissociation of emetic potential from the developmental novel compounds. We have worked to dissociate emetic potential from developmental compounds such as PD4 inhibitors with industrial collaborations.My area of research interest is in gastrointestinal motility and emesis. In the gastrointestinal motility research, I have established many in-vitro techniques. I have developed probably the best model to study highly complex and extremely useful peristaltic reflex in many species including guinea -pigs and mice and in various gastrointestinal regions including the ileum and colon.In the emesis side, our focus had been on developing new antiemetic therapy. We have investigated neurokinin and various other agents in collaboration with different pharmaceutical industries. Another area of expertise in the emesis research had been in the dissociation of emetic potential from the developmental novel compounds. We have worked to dissociate emetic potential from developmental compounds such as PD4 inhibitors with industrial collaborations.My area of research interest is in gastrointestinal motility and emesis. In the gastrointestinal motility research, I have established many in-vitro techniques. I have developed probably the best model to study highly complex and extremely useful peristaltic reflex in many species including guinea -pigs and mice and in various gastrointestinal regions including the ileum and colon.In the emesis side, our focus had been on developing new antiemetic therapy. We have investigated neurokinin and various other agents in collaboration with different pharmaceutical industries. Another area of expertise in the emesis research had been in the dissociation of emetic potential from the developmental novel compounds. We have worked to dissociate emetic potential from developmental compounds such as PD4 inhibitors with industrial collaborations.Current ProjectsDevelopment of in vitro peristalsis modelCurrent ProjectsDevelopment of in vitro peristalsis modelCurrent ProjectsDevelopment of in vitro peristalsis modelResearch CollaborationsSK Life Sciences, New Jersey, USA (£5198.00; 2013) SK Life Sciences, New Jersey, USA ConsultancySK Life Sciences, New Jersey, USA (£27,812.00; 2009) SK Life Sciences, New Jersey, USA (£27,812.00; 2009) Investigation of the prokinetic effect of 5-HT4 receptor ligandBBSRC Case Studentship with GSK (£81,000; 2004). Modulation of peristalsis by endogenous mediatorsGSK, UK (£21,555; 2004) Comparison of abilities of alvimopamGSK, UK (£73,966; 2001) Enteric Nerve Reflex Functions in Mouse Gastrointestinal TractLaboratories Dr. Esteeve, SPAIN (£7400, 2004, with Prof. Naylor) 5-HT7 receptors and GI activityArakis Ltd, UK (£55600, 2002, with Prof. Naylor) Investigation of potentiation of antiemetic effect with selective isomersArakis Ltd, UK (£51816, 2002, with Prof. Naylor) Testing of differential effect of isomers on emesis in the ferretsArakis Ltd, UK (£28426, 2001, with Prof. Naylor) Testing Arakis compounds to antagonize drug induced emesis in the ferret modelNovartis Horsham Research Centre, UK (£42887, 2001, with Prof. Naylor) Testing of Novartis PDE4 inhibitorsHoffMann La Roche, Basel, Switzerland (£34652, 2001, with Prof. Naylor) Evaluation of the antiemetic effect of test compoundsMerck Sharp & Dohme, UK (£27708, 2000, wiResearch CollaborationsSK Life Sciences, New Jersey, USA (£5198.00; 2013) SK Life Sciences, New Jersey, USA ConsultancySK Life Sciences, New Jersey, USA (£27,812.00; 2009) SK Life Sciences, New Jersey, USA (£27,812.00; 2009) Investigation of the prokinetic effect of 5-HT4 receptor ligandBBSRC Case Studentship with GSK (£81,000; 2004). Modulation of peristalsis by endogenous mediatorsGSK, UK (£21,555; 2004) Comparison of abilities of alvimopamGSK, UK (£73,966; 2001) Enteric Nerve Reflex Functions in Mouse Gastrointestinal TractLaboratories Dr. Esteeve, SPAIN (£7400, 2004, with Prof. Naylor) 5-HT7 receptors and GI activityArakis Ltd, UK (£55600, 2002, with Prof. Naylor) Investigation of potentiation of antiemetic effect with selective isomersArakis Ltd, UK (£51816, 2002, with Prof. Naylor) Testing of differential effect of isomers on emesis in the ferretsArakis Ltd, UK (£28426, 2001, with Prof. Naylor) Testing Arakis compounds to antagonize drug induced emesis in the ferret modelNovartis Horsham Research Centre, UK (£42887, 2001, with Prof. Naylor) Testing of Novartis PDE4 inhibitorsHoffMann La Roche, Basel, Switzerland (£34652, 2001, with Prof. Naylor) Evaluation of the antiemetic effect of test compoundsMerck Sharp & Dohme, UK (£27708, 2000, with Prof. Naylor) Examination of the antiemtic effects of test compoundsShering-Plough Research Institute, New Jersey, USA (£88268, 2000, with Prof. Naylor) Compounds as an antiemetic agent in ferretsSmithKline Beecham, UK (£12218, 1999, with Prof. Naylor) Ferret Model of EmesisNovartis Horsham Research Centre, UK (£26282, 1999, with Prof. Naylor) Emetic Potential of 4 Test compoundsHoffMann La Roche, Basel, Switzerland (£115085, 1999, with Prof. Naylor) Emesis experiments to examine antiemetic effect of Roche compoundsCell Tech R & D Ltd, UK (£159125, 1999, with Prof. Naylor) Investigation of Tramadol EnantiomersZambon Group, Italy (£50394, 1998) Research on Phosphodiesterase inhibitorsParke-Davis Neuroscience Research Centre, UK (£11081, 1997, with Prof. Naylor) Neurokinin antagonists as antiemeticsSandoz Institute for Medical Research, UK (£17209, 1995, with Prof. Naylor) Investigation of role of neurokininsParke-Davis Neuroscience Research Centre, UK (£34835, 1995, with Prof. Naylor) Neurokinin antagonists as antiemetic agentsParke-Davis Neuroscience Research Centre, UK (£8165, 1995, with Prof. Naylor) Investigation of a peripheral treatmentParke-Davis Neuroscience Research Centre, UK (£38415, 1995, with Prof. Naylor) Anti-emtic activity of CGP A & CGP BCell Tech R & D Ltd, UK (£405512, 1995, with Prof. Naylor) Study on CHI066 Short term ContractParke-Davis Neuroscience Research Centre, UK (£7351, 1995, with Prof. Naylor) Investigation of the peripheral administration
